P386 Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab. (27th May 2021)

• Record Type: Journal Article
• Authors: Mardare, R; Burgess, N; Studart, D; Deb, P; Gasparetto, M; Croft, N; Naik, S; Kadir, A
• Is Part Of: Journal of Crohn's and colitis. Volume 15(2021)Supplement 1
• Page Start: S397
• Page End: S398
• Publication Date: 2021-05-27
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjab076.510
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: In 2018, our Trust approved the use of vedolizumab in children with Ulcerative Colitis (UC) and ustekinumab in children with Crohn's Disease (CD). At the time, access to these drugs for children was only possible through research studies. Our aim was to assess the efficacy and safety of these novel treatments in our cohort. Methods: We conducted an observational single centre cohort study. Data was obtained from our electronic system, Cerner Millennium, and Infoflex database. Analysis was performed using SPSS. Results: 27 children were treated with vedolizumab or ustekinumab with 1 receiving both. All patients had failed anti-TNF medication, except 1 research patient who commenced on vedolizumab at diagnosis. Conclusion: In children with refractory IBD failing anti-TNF treatment, vedolizumab and ustekinumab are effective and safe alternatives for inducing and maintaining remission, avoiding major invasive surgery.